Floatz logo

LIDOCAINE

Central Neuropathic Pain

Brigham and Women's HospitalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Central Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
ds-5565
Daiichi Sankyo Co., Ltd.
Phase 3BB
Dextromethorphan
Brigham and Women's Hospital
Phase 2B
Adezunap
Apurano Pharmaceuticals GmbH
Phase 3B
Crisugabalin
Haisco Pharmaceutical Group Co., Ltd.
Phase 3B

View all 9 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →